TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genfit SA ( (GNFT) ) just unveiled an update.
On November 10, 2025, GENFIT presented promising preclinical data for its investigational drug G1090N at The Liver Meeting® 2025. The data demonstrated significant efficacy in reducing systemic inflammation and improving organ function in ACLF disease models. The company anticipates safety data from a Phase 1 study in healthy volunteers and initial efficacy signals by the end of 2025. These developments could significantly impact GENFIT’s clinical development pipeline and strengthen its position in addressing unmet needs in liver disease treatment.
The most recent analyst rating on (GNFT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall stock score is primarily influenced by its financial performance, which shows a positive recovery trajectory. However, technical indicators suggest bearish momentum, and the valuation is weak due to the negative P/E ratio and lack of dividend yield. These factors collectively result in a moderate overall score.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing therapies for rare and life-threatening liver diseases. With a strong emphasis on conditions such as Acute-on-Chronic Liver Failure (ACLF), Acute Decompensation (AD), and Hepatic Encephalopathy (HE), the company has a diverse R&D portfolio. GENFIT is also known for its diagnostic solutions and has achieved regulatory approval for its drug Iqirvo® for Primary Biliary Cholangitis (PBC) in several regions.
Average Trading Volume: 6,463
Technical Sentiment Signal: Strong Sell
Current Market Cap: $197.5M
See more insights into GNFT stock on TipRanks’ Stock Analysis page.